Comparison of pegfilgrastim on day 2 vs. day 4 as primary prophylaxis of intense dose-dense chemotherapy in patients with node-positive primary breast cancer within the prospective, multi-center GAIN study: (GBG 33)

Sibylle Loibl,Volkmar Mueller,Gunter von Minckwitz,B. Conrad,Claus-Henning Koehne,Stephan Kremers,H Forstbauer,Mattea Linder,Valentina Nekljudova,V. Moebus,Ago,Noggo study groups

Comparison of pegfilgrastim on day 2 vs. day 4 as primary prophylaxis of intense dose-dense chemotherapy in patients with node-positive primary breast cancer within the prospective, multi-center GAIN study: (GBG 33)

2011

Sibylle Loibl
Volkmar Mueller
Gunter von Minckwitz
B. Conrad
Claus-Henning Koehne
Stephan Kremers
H Forstbauer
Mattea Linder
Valentina Nekljudova
V. Moebus
Ago
Noggo study groups

Background Preliminary data suggest that pegfilgrastim given on day 4 (P4) might be superior to pegfilgrastim on day 2 (P2) in reducing grade 4 leucopenia.

Keywords:

Neutropenia
Breast cancer
Intensive care medicine
Dose-dense chemotherapy
Medicine
Pegfilgrastim
Oncology
in patient
primary breast cancer
Internal medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations